NeuroPace Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

NeuroPace hat ein Gesamteigenkapital von $14.3M und eine Gesamtverschuldung von $58.0M, was einen Verschuldungsgrad von 404.7% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $98.9M bzw. $84.5M.

Wichtige Informationen

404.7%

Verhältnis von Schulden zu Eigenkapital

US$58.04m

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	US$58.95m
Eigenkapital	US$14.34m
Gesamtverbindlichkeiten	US$84.51m
Gesamtvermögen	US$98.85m

Jüngste Berichte zur Finanzlage

Is NeuroPace (NASDAQ:NPCE) Weighed On By Its Debt Load?

Apr 12

Recent updates

Is NeuroPace (NASDAQ:NPCE) Weighed On By Its Debt Load?

Apr 12

NeuroPace: Picking Up The Pace

Feb 25

Why Investors Shouldn't Be Surprised By NeuroPace, Inc.'s (NASDAQ:NPCE) 58% Share Price Surge

Jan 22

NeuroPace, Inc. (NASDAQ:NPCE) Stock Rockets 39% But Many Are Still Ignoring The Company

Apr 17

NeuroPace announces U.S. distribution agreement with DIXI Medical

Aug 11

NeuroPace EPS misses by $32.45, beats on revenue; issues guidance

Jun 03

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: NPCEDie kurzfristigen Aktiva des Unternehmens ($84.3M) übersteigen seine kurzfristigen Passiva ($13.1M).

Langfristige Verbindlichkeiten: NPCEDie kurzfristigen Vermögenswerte des Unternehmens ($84.3M) übersteigen seine langfristigen Verbindlichkeiten ($71.4M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: NPCE über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: Es liegen keine ausreichenden Daten vor, um festzustellen, ob das Verhältnis von Schulden zu Eigenkapital in den letzten 5 Jahren gesunken ist ( NPCE).

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: NPCE auf der Grundlage seines derzeitigen freien Cashflows über eine ausreichende Liquiditätsreserve für mehr als 3 Jahre verfügt.

Vorhersage Cash Runway: NPCE über eine ausreichende Liquiditätsreserve für mehr als 3 Jahre verfügt, wenn der freie Cashflow weiterhin mit historischen Raten von 2.1 % pro Jahr zurückgeht

NeuroPace Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Is NeuroPace (NASDAQ:NPCE) Weighed On By Its Debt Load?

Recent updates

NeuroPace, Inc. Reaffirms Earnings Guidance for the Year 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Forecast to breakeven in 2026

NeuroPace, Inc., Annual General Meeting, Jun 07, 2024

NeuroPace, Inc. to Report Q1, 2024 Results on May 08, 2024

Is NeuroPace (NASDAQ:NPCE) Weighed On By Its Debt Load?

Consensus EPS estimates upgraded to US$1.17 loss

New minor risk - Profitability

NeuroPace, Inc. Provides Earnings Guidance for the Year 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Forecast to breakeven in 2026

NeuroPace: Picking Up The Pace

New minor risk - Share price stability

NeuroPace, Inc. to Report Q4, 2023 Results on Mar 05, 2024

NeuroPace, Inc Announces Resignation of Irina Ridley as Chief Legal Officer and Corporate Secretary

Why Investors Shouldn't Be Surprised By NeuroPace, Inc.'s (NASDAQ:NPCE) 58% Share Price Surge

NeuroPace, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter Ended December 31, 2023

Price target increased by 15% to US$10.50

Forecast to breakeven in 2026

Chief Medical Officer notifies of intention to sell stock

NeuroPace, Inc. Announces Early Completion of Patient Enrollment in NAUTILUS Pivotal Study

Chief Medical Officer notifies of intention to sell stock

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Revenue and earnings growth

Consensus estimates of losses per share improve by 12%

NeuroPace, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Price target increased by 11% to US$7.80

New minor risk - Share price stability

Consensus revenue estimates increase by 14%

NeuroPace, Inc. Revises Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

NeuroPace, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Neuropace, Inc. Announces Board Member Changes

NeuroPace, Inc. Revises Earnings Guidance for the Year 2023

Price target increased by 7.7% to US$7.00

NeuroPace, Inc. (NASDAQ:NPCE) Stock Rockets 39% But Many Are Still Ignoring The Company

Full year 2022 earnings: EPS exceeds analyst expectations

Price target increased by 11% to US$6.50

NeuroPace, Inc. to Report Q4, 2022 Results on Mar 02, 2023

NeuroPace, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2022

Neuropace, Inc. Announces First Patient with Lennox-Gastaut Syndrome (Lgs) Was Treated in Its Feasibility Investigational Device Exemption (Ide) Study

Price target decreased to US$6.38

Price target decreased to US$6.38

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

NeuroPace, Inc. Revises Earnings Guidance for the Fiscal Year 2022

NeuroPace, Inc. to Report Q3, 2022 Results on Nov 08, 2022

NeuroPace Inc. Announces First Patient Implanted in NAUTILUS Pivotal Study for the Treatment of Idiopathic Generalized Epilepsy

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Neuropace, Inc. Provides Revenue Guidance for 2022

NeuroPace announces U.S. distribution agreement with DIXI Medical

NeuroPace, Inc. to Report Q2, 2022 Results on Aug 11, 2022

NeuroPace, Inc.(NasdaqGM:NPCE) dropped from Russell 2000 Growth Index

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

NeuroPace, Inc. Provides Revenue Guidance for the Year 2022

Neuropace Announces First Patient Treated in Pivotal Study Evaluating the Rns System in Adolescents

Price target decreased to US$11.60

NeuroPace, Inc., Annual General Meeting, Jun 13, 2022

NeuroPace, Inc. to Report Q1, 2022 Results on May 12, 2022

Consensus EPS estimates fall by 75%

Full year 2021 earnings: EPS exceeds analyst expectations

Full year 2021 earnings: EPS exceeds analyst expectations

NeuroPace, Inc. to Report Q4, 2021 Results on Mar 10, 2022

Third quarter 2021 earnings released: US$0.34 loss per share

Less than half of directors are independent

Consensus forecasts updated

NeuroPace, Inc. Reiterates Financial Guidance for the Full Year of 2021

NeuroPace, Inc. Announces the Broad Launch of Its nSight Platform

NeuroPace Awards Five-Year National Institutes of Health Grant Funding of More Than $9 Million to Study RNS System in Patients with Lennox-Gastaut Syndrome

NeuroPace, Inc. Provides Revenue Guidance for the Second Quarter and Full Year of 2021

Forecast to breakeven in 2025

NeuroPace EPS misses by $32.45, beats on revenue; issues guidance

Chairman of the Board recently bought US$850k worth of stock

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital